ALK-Abelló A/S (LON:0OIR)

London flag London · Delayed Price · Currency is GBP · Price in DKK
158.20
+2.70 (1.74%)
At close: Feb 13, 2025
20.16%
Market Cap 3.88B
Revenue (ttm) 613.98M
Net Income (ttm) 90.37M
Shares Out n/a
EPS (ttm) 0.41
PE Ratio 42.89
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 3,162
Average Volume 19,105
Open 155.80
Previous Close 155.50
Day's Range 155.10 - 158.20
52-Week Range 11.05 - 20.60
Beta 0.63
RSI 51.95
Earnings Date Feb 19, 2025

About ALK-Abelló

ALK-Abelló A/S operates as an allergy solutions company in Europe, North America, and internationally. Its product portfolio includes GRAZAX/GRASTEK, RAGWITEK/RAGWIZAX, ACARIZAX/ODACTRA, MITICURE, CEDARCURE, and ITULAZAX/ITULATEK for treatment of allergic rhinitis and allergic asthma. The company offers allergy immunotherapy products in the form of injections, sublingual drops, and tablets for the treatment of various allergies, including grass, ragweed, house dust mite, Japanese cedar, tree, and food. It also provides consumer healthcare solut... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 1923
Employees 2,824
Stock Exchange London Stock Exchange
Ticker Symbol 0OIR
Full Company Profile

Financial Performance

In 2024, ALK-Abelló's revenue was 5.54 billion, an increase of 14.78% compared to the previous year's 4.82 billion. Earnings were 815.00 million, an increase of 67.70%.

Financial numbers in DKK Financial Statements

News

There is no news available yet.